脂肪酸合酶
脂肪酸合成
非酒精性脂肪肝
疾病
计算生物学
脂肪肝
生物信息学
生物
医学
脂肪酸
生物化学
内科学
作者
SJ Singh,Chandrabose Karthikeyan,N. S. Hari Narayana Moorthy
出处
期刊:Recent Patents on Anti-cancer Drug Discovery
[Bentham Science]
日期:2024-02-01
卷期号:19 (1): 37-56
被引量:1
标识
DOI:10.2174/1574892818666230112170003
摘要
Fatty acid synthase (FASN), is a key metabolic enzyme involved in fatty acid biosynthesis and is an essential target for multiple disease progressions like cancer, obesity, NAFLD, etc. Aberrant expression of FASN is associated with deregulated energy metabolism of cells in these diseases.This article provides a summary of the most recent developments in the discovery of novel FASN inhibitors with potential therapeutic uses in cancer, obesity, and other metabolic disorders such as nonalcoholic fatty liver disease from 2016 to the present. The recently published patent applications and forthcoming clinical data of FASN inhibitors from both academia and the pharma industries are also highlighted in this study.The implication of FASN in multiple diseases has provided an impetus for developing novel inhibitors by both pharma companies and academia. Critical analysis of the patent literature reveals the exploration of diverse molecular scaffolds to identify potential FASN inhibitors that target the different catalytic domains of the enzyme. In spite of these multifaceted efforts, only one molecule, TVB-2640, has reached phase II trials for nonalcoholic steatohepatitis (NASH) and many malignancies. However, thecombined efforts of pharma companies to produce several FASN inhibitors might facilitate the clinical translation of this unique class of inhibitors. Nevertheless, concerted efforts towards developing multiple FASN inhibitors by pharma companies might facilitate the clinical translation of this novel class of inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI